UBE2C is a marker of unfavorable prognosis in bladder cancer after radical cystectomy.

It has been suggested that ubiquitin-conjugating enzyme E2C (UBE2C, also known as UBCH10) represents a promising cancer biomarker. However, the clinicopathological or prognostic significance as well as the functions of UBE2C in bladder cancer are largely unknown. To investigate the significance of UBE2C expression in bladder cancer, immunohistochemical analysis was performed using a tissue microarray. UBE2C positivity was observed in 51 of 82 (62%) bladder urothelial carcinoma cases treated with radical cystectomy. In contrast, UBE2C was negative in all of the non-neoplastic urothelium examined. UBE2C positivity was significantly associated with higher tumor stage (p=0.0061) and presence of lymphovascular invasion (p=0.0045). In addition, UBE2C positivity was significantly associated with shorter cancer-specific survival after cystectomy (log rank p=0.0017; multivariate hazard ratio, 2.49; 95% confidence interval, 1.09-5.71). Small interfering RNA-mediated suppression of UBE2C in UM-UC-3 bladder cancer cells inhibited cell proliferation in vitro. Taken together, our results suggest that UBE2C is a novel prognostic biomarker as well as a potential therapeutic target in bladder cancer.

[1]  G. Ergun,et al.  The prognostic significance of advanced age in patients with bladder cancer treated with radical cystectomy , 2009, BJU international.

[2]  E. Messing,et al.  Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. , 2005, Urology.

[3]  Viji M. Draviam,et al.  Anaphase initiation is regulated by antagonistic ubiquitination and deubiquitination activities , 2007, Nature.

[4]  K. Mimori,et al.  Identification of overexpressed genes in hepatocellular carcinoma, with special reference to ubiquitin‐conjugating enzyme E2C gene expression , 2007, International journal of cancer.

[5]  Hui-xiang Ji,et al.  High expression level of BLCA-4 correlates with poor prognosis in human bladder cancer. , 2012, International journal of clinical and experimental pathology.

[6]  Liang Cheng,et al.  Staging and reporting of urothelial carcinoma of the urinary bladder , 2009, Modern Pathology.

[7]  S. Shariat,et al.  Immunohistochemical biomarkers for bladder cancer prognosis , 2011, International journal of urology : official journal of the Japanese Urological Association.

[8]  G. Netto.  Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet? , 2012, Nature Reviews Urology.

[9]  Per-Uno Malmström,et al.  Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer. , 2013, The American journal of pathology.

[10]  M. Fukayama,et al.  Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro. , 2010, Human pathology.

[11]  Y. Soini,et al.  8-hydroxydeguanosine and nitrotyrosine are prognostic factors in urinary bladder carcinoma. , 2011, International journal of clinical and experimental pathology.

[12]  N. Pavlidis,et al.  Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Hui Zhang,et al.  Ubiquitin-conjugating enzyme UBE2C: molecular biology, role in tumorigenesis, and potential as a biomarker , 2012, Tumor Biology.

[14]  H. Ozen.  Bladder cancer. , 1998, Current opinion in oncology.

[15]  Z. Jehan,et al.  Bortezomib stabilizes mitotic cyclins and prevents cell cycle progression via inhibition of UBE2C in colorectal carcinoma. , 2011, The American journal of pathology.

[16]  Francesco Hofmann,et al.  Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin , 2004, Oncogene.

[17]  Hiroyuki Aburatani,et al.  Identification of Toll-Like Receptor 3 as a Potential Therapeutic Target in Clear Cell Renal Cell Carcinoma , 2007, Clinical Cancer Research.

[18]  J. V. van Deursen,et al.  Overexpression of the E2 ubiquitin–conjugating enzyme UbcH10 causes chromosome missegregation and tumor formation , 2010, The Journal of cell biology.

[19]  Akira Nakagawara,et al.  UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme. , 2003, Cancer research.

[20]  R. Lotan,et al.  Identification of Gene Signatures and Molecular Markers for Human Lung Cancer Prognosis using an In vitro Lung Carcinogenesis System , 2009, Cancer Prevention Research.

[21]  M. Guida,et al.  UbcH10 expression may be a useful tool in the prognosis of ovarian carcinomas , 2007, Oncogene.

[22]  D. Grignon.  The current classification of urothelial neoplasms , 2009, Modern Pathology.

[23]  D. Beer,et al.  Expression and effect of inhibition of the ubiquitin-conjugating enzyme E2C on esophageal adenocarcinoma. , 2006, Neoplasia.

[24]  T. Rajkumar,et al.  Dominant negative Ubiquitin-conjugating enzyme E2C sensitizes cervical cancer cells to radiation , 2012, International journal of radiation biology.

[25]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[26]  Marc W. Kirschner,et al.  Autonomous regulation of the anaphase-promoting complex couples mitosis to S-phase entry , 2004, Nature.

[27]  Validation of UBE2C protein as a prognostic marker in node-positive breast cancer , 2009, British Journal of Cancer.

[28]  Lei Jiang,et al.  UbcH10 expression provides a useful tool for the prognosis and treatment of non-small cell lung cancer , 2012, Journal of Cancer Research and Clinical Oncology.

[29]  Hirokuni Ikeda,et al.  Clinicopathological relevance of UbcH10 in breast cancer , 2009, Cancer science.

[30]  Yair Lotan,et al.  Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy , 2008, Cancer.

[31]  Y. Lotan,et al.  Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. , 2007, European urology.

[32]  M. Kruhøffer,et al.  UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas , 2005, British Journal of Cancer.

[33]  A. Hershko,et al.  Dominant-negative cyclin-selective ubiquitin carrier protein E2-C/UbcH10 blocks cells in metaphase. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[34]  S. Shariat,et al.  Bladder cancer: Nomogram aids clinical decision making after radical cystectomy , 2010, Nature Reviews Urology.